Hot Products
| Catalog No. | Information |
| CFN91122 | Ardisicrenoside A Reference standards. |
| CFN93320 | Arecaidine Arecaidine has tumorgenicity. |
| CFN93357 | Arecaidine hydrochloride Arecaidine hydrochloride may have carcinogenesis. |
| CFN90799 | Arecoline hydrobromide Arecoline hydrobromide is formerly used as a cholinergic agent, it is a hypotensive agent. Arecoline hydrobromide is purgative, vermifuge and taenifuge agents in veterinary medicine. It induces rat hepatic CYP2 B by promoting nuclear translocation of CAR, the regulation of it on rat hepatic CYP2 B largely involve transcriptional activation of the gene,partially involve the post-translational modification of CYP2 B protein. |
| CFN98578 | Arenobufagin Arenobufagin is a potent Na + /K + pump inhibitor, and is also a specific inhibitor of VEGF-mediated angiogenesis. Arenobufagin has antineoplastic effect that involves cross talk between apoptosis and autophagy via inhibition of the PI3K/Akt/mTOR pathway. |
| CFN95281 | Arganine B |
| CFN89201 | Arglabin Arglabin has antiatherogenic effects, it may represent a new promising compound to treat inflammation and type 2 diabetes mellitus development, it can attenuate inflammation, protect pancreatic β-cells from apoptosis, and prevent Type 2 diabetes mellitus development in ApoE2Ki mice on a chronic high-fat diet. Arglabin shows promising antitumor activity against different tumor cell lines, Arglabin-DMA inhibits cell proliferation of a variety of tumor types with IC(90)s in the range of 0.85 to 5.0 microg/ml. |
| CFN89328 | Aristola-1(10),8-dien-2-one Reference standards. |
| CFN96013 | Aristolactam AII Aristolactam AII has cytotoxic activity, it also shows platelet aggregation inhibitory activity. |
| CFN97551 | Aristolactam AIIIa Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid. |
